Veracyte (VCYT)

• Market cap: $2.99B
• 1 day: 6.65%
• 5 days: 1.19%
• 1 month: 18.21%
• 3 months: 21.06%
• 6 months: 75.56%
• Year to date: 42.88%
• 1 year: 50.35%
• 5 years: 50.81%
• 10 years: 498.62%
• Sector: Healthcare
• Industry: Medical Laboratories

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

911% more call options, than puts

Call options by funds: $4.58M | Put options by funds: $453K

221% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 24

55% more capital invested

Capital invested by funds: $1.79B [Q2] → $2.78B (+$986M) [Q3]

22% more funds holding

Funds holding: 236 [Q2] → 289 (+53) [Q3]

6% less repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 90

1.27% less ownership

Funds ownership: 108.02% [Q2] → 106.75% (-1.27%) [Q3]

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $28 28% downside
• Avg. target: $40 2% upside
• High target: $46 17% upside

9 analyst ratings

• positive: 8 89%
• neutral: 0 0%
• negative: 1 11%

Morgan Stanley Tejas Savant 33% 1-year accuracy 3 / 9 met price target	28% downside $28	Underweight Maintained	18 Nov 2024
Scotiabank Sung Ji Nam 45% 1-year accuracy 10 / 22 met price target	12% upside $44	Sector Outperform Maintained	8 Nov 2024
Goldman Sachs Matthew Sykes 43% 1-year accuracy 12 / 28 met price target	3% downside $38	Buy Maintained	7 Nov 2024
UBS	18% upside $46	Buy Maintained	7 Nov 2024
Needham Mike Matson 65% 1-year accuracy 62 / 95 met price target	12% upside $44	Buy Maintained	7 Nov 2024